Hyperliquid Strategies is a Nasdaq-listed treasury whose equity is a claim on a single token rather than on an operating franchise. The first full fiscal year after the December listing was spent converting a reverse-merger shell into the largest public pile of HYPE, the native asset of the Hyperliquid Layer One chain. That conversion is now complete enough that the residual biotech story is gone and the residual accounting noise is mostly tax. The investment debate is whether the wrapper compounds token exposure per share or merely recycles issued stock into a more expensive version of the same bet.
Reported profit looks like an operating company that suddenly earned hundreds of millions. Almost none of it is cash from customers. Staking and validator commissions were only $10 million against a treasury measured in the billions, while the income statement is dominated by fair-value swings on the token. The market is therefore not buying a business. It is buying a taxed and potentially dilutive claim on one protocol's native asset, packaged for brokerage accounts that cannot easily hold the coin itself.
Year-end assets crossed $2 billion after the token more than doubled in the spring quarter and the company kept issuing stock to buy more. A later expansion of the Chardan purchase line, with a floor price that now sits near the tape, makes the next stretch a test of issuance discipline. The open question is whether tokens per share rise faster than the share count.